Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Merck & Co., Inc. Director's Dealing 2013

May 8, 2013

284_dirs_2013-05-08_47f0e424-1566-48ed-8bf8-53e182a7ae9c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co. Inc. (MRK)
CIK: 0000310158
Period of Report: 2013-05-06

Reporting Person: Kuhlik Bruce N (Exe V-P & Gen Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-05-06 Common Stock M 117646.0000 $33.4900 Acquired 210073.0530 Direct
2013-05-06 Common Stock M 89552.0000 $36.5600 Acquired 299625.0530 Direct
2013-05-06 Common Stock M 42800.0000 $23.4500 Acquired 342425.0530 Direct
2013-05-06 Common Stock S 249998.0000 $45.0505 Disposed 92427.0530 Direct
2013-05-07 Common Stock M 33144.0000 $0.0000 Acquired 125571.0530 Direct
2013-05-07 Common Stock F 17186.0000 $44.9800 Disposed 108385.0530 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-05-06 Stock Option (right to buy) $23.4500 M 42800.0000 Disposed 2019-04-23 Common Stock (42800.0000) Direct
2013-05-06 Stock Option (right to buy) $36.5600 M 89552.0000 Disposed 2021-05-03 Common Stock (89552.0000) Direct
2013-05-06 Stock Option (right to buy) $44.9800 A 148148.0000 Acquired 2023-05-05 Common Stock (148148.0000) Direct
2013-05-06 Stock Option (right to buy) $33.4900 M 117646.0000 Disposed 2020-05-06 Common Stock (117646.0000) Direct
2013-05-07 Restricted Stock Unit $ M 33144.0000 Disposed 2013-05-07 Common Stock (33144.0000) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0000 to $45.1700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2: Holdings include shares acquired in dividend reinvestment transactions.

F3: The option vests in three equal annual installments beginning May 6, 2014.

F4: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.